Characteristics of human oral microbiome and its non-invasive diagnostic value in chronic kidney disease. Issue 5 (27th May 2022)

• Record Type: Journal Article
• Authors: Guo, Shiyuan; Wu, Ge; Liu, Wenli; Fan, Yajuan; Song, Wengang; Wu, Jian; Gao, Dan; Gu, Xi; Jing, Sanhui; Shen, Quanquan; Ren, Lingyan; Dong, Yindi; Liu, Zhangsuo
• Is Part Of: Bioscience reports. Volume 42:Issue 5(2022)
• Publication Date: 2022-05-27
• Subjects: Chronic kidney disease -- Microbial biomarker -- Miseq sequencing -- Non-invasive diagnostic value -- Oral microbiome; Molecular biology -- Periodicals; Cytology -- Periodicals; 572.8
• DOI: 10.1042/BSR20210694
• Languages: English
• ISSNs: 0144-8463

Abstract

Abstract: Background: Morbidity of chronic kidney disease (CKD) is increased, with many complications and high mortality rates. The characteristics of oral microbiome in CKD patients have not been reported. This study aims to analyze the oral microbiome, and to demonstrate the potential of microbiome as noninvasive biomarkers for CKD patients. Methods: The study collected 253 oral samples from different regions of China (Central China and East China) prospectively and finally 235 samples completed Miseq sequencing, including 103 samples from CKD patients and 132 healthy controls (HCs). Results: Compared with HCs ( n =88), the oral microbial diversity in CKD patients ( n =44) was increased. Fourteen genera including Streptococcus, Actinomyces and Leptotrichia were enriched, while six genera including Prevotella and Haemophilus were decreased in CKD patients. Moreover, 49 predicted microbial gene functions including arginine metabolism and tryptophan metabolism increased, while 55 functions including Ribosome and DNA repair recombination proteins decreased. Furthermore, correlation analysis demonstrated that 38 operational taxonomic units (OTUs) were closely related to 5 clinical indicators of CKD. Notably, 7 optimal biomarkers were identified using random forest model, and the classifier model respectively reached an area under the curve (AUC) of 0.9917 and 0.8026 in the discovery and validation phase, achieving a cross-region validation. Conclusions: We first illustrated the characteristics of the oral microbiome of patients with CKD, identified the potential of oral microbial makers as noninvasive tools for the diagnosis of CKD and achieved cross-region validation.